Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 09, 2022 16:02 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Reports Second Quarter 2022 Financial Results

U.S. FDA Clearance on Potential Pivotal Phase 2 Trial of ALLO-501A Anticipated in Coming Weeks Expected to be the Industry’s First Allogeneic CAR T Phase 2 Pivotal TrialClearance to Cover ALPHA2...
August 03, 2022 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
July 27, 2022 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022

SOUTH SAN FRANCISCO, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
July 12, 2022 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Appoints Scientific Pioneer Stephen Mayo to its Board of Directors

SOUTH SAN FRANCISCO, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
June 08, 2022 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma

RMAT Designation Follows Positive Data from ALLO-501A ALPHA2 Trial in Heavily Pretreated Patients with Relapsed or Refractory Large B cell Lymphoma (LBCL) Data Presented at the American Society of...
May 19, 2022 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Cells Derived from Healthy, Younger Donors were More Abundant with Greater Fitness and Cancer Killing Potential Than Cells Derived from Patients with CancerFindings Underscore Potential of Allogeneic...
May 09, 2022 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Named 2022 Bay Area “Best Place to Work” by San Francisco Business Times and Silicon Valley Business Journal

Allogeneic CAR T Pioneer Highest Ranked Bay Area Biotech in the Large Company Category Based on Employee Survey SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics,...
May 04, 2022 16:02 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Reports First Quarter 2022 Financial Results

Pivotal Phase 2 ALPHA2 Trial of ALLO-501A in R/R Large B Cell Lymphoma Planned to Commence Mid 2022 Using Product from Cell Forge 1 (CF1) CF1 is Projected to Support the Manufacture of ~20,000 Doses...
April 28, 2022 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Appoints Susan Lundeen as Chief People Officer

New Position Aimed at Attracting, Retaining, and Cultivating a Best-in-Class Workforce as Allogene Scales its Operations for its Next Stage of Growth SOUTH SAN FRANCISCO, Calif., April 28, 2022 ...
April 27, 2022 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics to Report First Quarter 2022 Financial Results on May 4, 2022

Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage...